Дата:	--/--/-- --:--:--
Id события:	E5L5V436T
Тип действия:	ACQUISITION
Статус действия:	ANNOUNCED
Символ покупателя:
Целевой символ:	CRNX
Обновлено:	--/--/-- --:--:--
Цена покупки за акцию:	85
Цена за акцию в валюте:	USD
Ссылки на новости:	https://www.businesswire.com/news/home/20260706876183/en/

Action Notes

Vertex Pharmaceuticals Incorporated and Crinetics Pharmaceuticals, Inc a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026.